Introduction
Postoperative nausea and vomiting (PONV) is exceedingly common and occurs in approximately 30% of patients and up following general anesthesia. For patients with multiple risk factors, the chance of PONV can be as high as 80% [1]. Commonly recognized risk factors include female sex, non-smoking status, history of PONV or motion sickness, postoperative pain/opioid administration, use of volatile anesthetics, duration of anesthesia and surgery, as well as type of surgery (laparoscopic, gynecological, ENT, neurosurgery) [2].
When present, PONV can result in complications such as wound dehiscence, esophageal rupture, aspiration, increased intracranial pressure, pneumothorax, and severe dehydration - leading to delayed recovery and prolonged hospital length of stay [3].
Large observational studies and meta-analyses suggest that propofol as TIVA can reduce the incidence of PONV by 40–50% and by 17% when added to volatile anesthetics [4–7]. The antiemetic mechanism of propofol is related to its interaction with dopaminergic (D2) receptors in the chemoreceptor trigger zone of the brain, inhibitory effect on the limbic system, and its interaction with serotonergic (5-HT3) receptors [8]. However, these studies have typically excluded patients with a prior history of PONV or motion sickness, or limited PONV assessment to the post-anesthesia care unit (PACU).
To date, no studies have evaluated the efficacy of low-dose propofol infusion in preventing PONV among patients with a previous history of PONV and/or motion sickness who are undergoing elective laparoscopic surgery under general anesthesia. The objective of this study was to compare the incidence of PONV between a hybrid anesthesia technique using low-dose propofol infusion with sevoflurane and propofol-only TIVA in this high-risk patient population. We conducted a randomized controlled clinical trial to address this objective.
We hypothesized that propofol-based TIVA would be associated with a lower incidence of PONV compared with the hybrid regimen.
Methods
Study setting
This prospective, single-blind, randomized controlled clinical trial was conducted at Penn State Health Milton S. Hershey Medical Center from February 2024 to March 2025. The study received ethical approval from The Pennsylvania State University Institutional Review Board (IRB #00021935).
Written informed consent was obtained from all participants prior to their enrollment in the study. Name of trial registry: Prevention of Post-Operative Nausea and Vomiting With Propofol Infusion, NCT05759481 (https://register.clinicaltrials.gov/prs/app/template/EditProtocol.vm? listmode=Edit&uid=U0005QUB&ts=8&sid=S000CZ7P&cx=-qpj9tj), registered on 02/22/2023. Trial protocol and statistical analysis plan can be found on CATS IRB.
Study population
Adults 18 years or older were recruited. Inclusion criteria were: (1) undergoing general anesthesia for elective laparoscopic surgery (general, gynecologic or urologic), (2) patients’ self-disclosure of PONV and/or motion sickness, (3) and English-speaking. Exclusion criteria were: (1) any anti-nausea medication taken within 24 h prior to surgery, (2) unable to provide consent independently, (3) allergy or adverse reaction to propofol or sevoflurane, and (4) emergency surgery.
Study procedures
Randomization and blinding
The study was conducted in accordance with CONSORT guidelines. Randomization occurred after informed consent and prior to induction of anesthesia using https://www.randomizer.org/. Participants were blinded to group allocation.
Due to the nature of the interventions, attending anesthesiologists were not blinded. Postoperative follow up was conducted by a blinded member of the research team.
Standardized anesthesia protocol
Except for the group assignment, all other aspects of the anesthesia plan were standardized. Anesthesia was induced with propofol (1–2 mg/kg), fentanyl (0.5–1.5 mcg/kg), lidocaine (up to 1.5 mg/kg), and rocuronium (0.6 mg/kg) for tracheal intubation. Maintenance of anesthesia was according to the group assignment.
Group A received a hybrid anesthesia technique combining propofol infusion at 25 mcg/kg/min with sevoflurane (hereafter referred to as hybrid group) while Group B received propofol-only TIVA. In both groups, bispectral index (BIS) was maintained between 40 and 60, with adjustments to sevoflurane concentration in Group A and propofol infusion rate in Group B made at the discretion of the attending anesthesiologist. No other hypnotic/sedative agents, e.g., isoflurane, desflurane, nitrous oxide, ketamine, or dexmedetomidine, were allowed.
Analgesia was provided with fentanyl and/or hydromorphone and optional preoperative acetaminophen. Rocuronium was re-dosed as needed and reversed with sugammadex. Dexamethasone (4 mg) was given after induction and ondansetron (4 mg) at closure for all patients.
Intraoperative hemodynamic monitoring was per ASA standards. All patients received an initial crystalloid bolus (10 mL/kg) followed by maintenance infusion. Blood products were administered as clinically indicated.
Surgeons were permitted to administer local anesthetics for infiltration; however, no regional anesthetic techniques were permitted. Rescue antiemetics were prescribed at the discretion of the treating clinicians.
Data collection
In the PACU, nursing staff recorded any signs/symptoms of PONV as well as pain scores via visual analog scale (VAS) every 15 min for the first 2 h and then every hour until discharge from PACU. Rescue antiemetics were documented.
Following discharge from PACU, participants recorded all episodes of nausea (urge to vomit), retching (labored, spasmodic, rhythmic contractions of respiratory muscles without expulsion of gastric contents), and vomiting (forceful expulsion of gastric contents) experienced during the 24 h following surgery, as well as use of rescue antiemetic medications. These data were obtained via standardized patient questionnaires and follow-up telephone calls at 24 h by a blinded research team member. If participants could not be reached, a second telephone call was made at 48 h post-surgery.
If still unsuccessful, the participant was considered lost to follow-up. Participants with incomplete outcome data were excluded from the final analysis. All data were stored securely in REDCap.
Outcomes
The primary outcome was the cumulative incidence of PONV within 24 h postoperatively. Secondary outcomes included PONV in PACU and use of rescue antiemetics.
Statistical analysis
Based on a previous study reporting an incidence of nausea and vomiting of 62% in the sevoflurane group and 21% in the combination group (sevoflurane + propofol) [9], we calculated the minimum effective sample size using a likelihood test to compare two independent proportions, assuming 90% power and a 5% significance level. The required sample size was estimated to be 30 participants per arm (60 in total).
Data were analyzed using Stata version 18 (StataCorp LLC, College Station, TX). Normality of continuous variables was assessed visually and using the Shapiro-Wilk test. Due to non-normality of most continuous variables, mean and interquartile ranges (IQR) were reported.
Between-group comparison was conducted using Wilcoxon-Mann-Whitney test. Categorical variables were compared across the two groups using Pearson’s chi-squared test.
Exploratory post hoc logistic regression analyses were performed to adjust for age, gender, length of stay (LOS), duration of surgery and anesthetic. These analyses were considered hypothesis generating. Results were reported as odds ratios (ORs) with corresponding 95% confidence intervals.
A two-tailed p-value of < 0.05 was considered statistically significant.
Results
Baseline demographics and perioperative characteristics
A total of 65 patients completed the study: 32 patients in the hybrid group and 33 patients in the propofol-only TIVA group. Baseline demographic characteristics were similar between the groups. The median age was 40.5 years in the hybrid group and 40 years and propofol-only TIVA group (p = 0.42).
Both treatment and control groups were predominantly female (84% and 85%, respectively, p = 0.48). Median BMI (29.5 vs. 29, p = 0.56), smoking status (2 vs.
1, p = 0.57), and ASA status (p = 0.13) did not significantly differ between the two groups. (Table 1)
Table 1Patient demographics and perioperative characteristics, hypotension and morphine useHybrid(N = 32)Propofol-only TIVA(N = 33)p-values§Median [N]IQR [%]Median [N]IQR [%]Age40.528.5–594036–55Gender Female[27][84][28][85] Male[5][16][3][9]BMI29.524.5–37.52925–31Smoking[2][6][1][3]ASA 1[0][0][1][3] 2[19][59][24][73] 3[13][41][6][18]Duration Anesthesia (min)112.582–186.5.5169107.5–2500.02 Surgery (min)8662.5–146.5.5.5127.587–2230.02 LOS (hr)3.02.2–4.47.42.4–46.10.04No. of times MAP < 650.38 0[19][60][19][58] 1[6][18][2][6] 2[3][9][3][9] 3[2][6][5][15] 4[1][3][3][9] 5[1][3][0][0]Treatment for hypotension0.09 Epinephrine[0][0][1][3] Norepinephrine[5][16][6][18] Phenylephrine[4][13][4][12] Ephedrine[9][28][9][27]Vasoactive dose Epinephrine (mcg)--55–5- Norepinephrine (mcg)208–282216–153.4.40.83 Vasopressin (units)----- Phenylephrine (mcg)300100–1250400100–8001.00 Ephedrine (mg)7.55–15105–150.58VAS Pain scores 15 min post-surgery60–850–80.66 30 min post-surgery52–770–70.97 45 min post-surgery42–740–70.91 60 min post-surgery30–541–70.13 Total Morphine use (MME)2010–27.5.527.510–48.5.50.19Values are presented as median and interquartile range or number [percentage]. Percentages are rounded to the nearest whole number. § p-values were calculated using Wilcoxon-Mann-Whitney Test for continuous variables and Pearson’s chi-squared test for categorical variables. Comparison involving small cell counts and variables with non-normal distributions should be interpreted cautiously.
LOS refers to the hours spent in the hospital after being discharged from PACU. This is computed by: Hospital discharge time - PACU discharge time
Patients in the propofol-only TIVA group experienced a significantly longer duration of surgery (median time 86 vs. 127.5 min, p = 0.02) and anesthesia (112.5 vs. 169 min, p = 0.02).
Additionally, these patients had a significantly longer hospital length of stay (LOS) after discharge from PACU (median time 3 vs. 7.4 h, p = 0.04) (Table 1).
Intraoperative hypotension, defined as a mean arterial pressure (MAP) < 65 mmHg, occurred at similar frequencies and was not found to be significantly different between groups (p = 0.38). Vasopressor use was comparable between groups with no statistically significant difference in frequency (p = 0.09) or dosing.
Pain scores, measured using the Visual Analog Scale (VAS), and opioid usage, measured in morphine milligram equivalents (MME), were similar between groups. The median total MME administered on per patient in hybrid group was 20 MME vs. 27.5 MME per patient in propofol-only TIVA group (p = 0.19) (Table 1).
Postoperative nausea and vomiting
In the PACU, no statistically significant differences were observed in the incidence of PONV between the two groups {9 (28%) in the hybrid group vs. 7 (21%) in propofol-only group (p = 0.44)}. For both groups, nausea was the only element of PONV experienced in the PACU - no episodes of retching or vomiting were reported (Table 2).
Antiemetic medications that were administered in the PACU included droperidol, ondansetron, prochlorperazine, and promethazine. Ondansetron and promethazine were the most frequently administered agents.
Table 2Nausea/Vomiting and antiemetic useOutcomeHybrid (n = 32)Propofol-only TIVA (n = 33)Adjusted OR (95% CI)p-valuePONV, n (%)9 (28)7 (21)1.83 (0.52–6.48)0.34Antiemetic use, n (%)9 (28)7 (21)1.59 (0.51–4.92)0.48PACU descriptive items only OutcomeHybridPropofol-only TIVA Nausea episodes97 Retching episodes00 Vomiting episodes00 Droperidol use01 Ondansetron use45 Prochlorperazine use11 Promethazine use5224-hours post PACU OutcomeHybrid (n=32)Propofol-only TIVA (n=33)Adjusted OR (95% CI)p-valuePONV, n (%)19 (59)14 (42)1.59 (0.51–4.93)0.80Antiemetic use, n (%)12 (38)8 (24)1.84 (0.56–6.04)0.3124-hours post PACU descriptive items only OutcomeHybridPropofol-only TIVA Nausea episodes3050 Retching episodes38 Vomiting episodes619 Ondansetron use76 Prochlorperazine use14 Promethazine use63 Scopolamine patch20§ Data are presented as number (percentage) only unless otherwise indicated. §§Adjusted odds ratios (and their corresponding 95% CI and p-values) were derived from exploratory post hoc logistic regression analysis adjusting for age, gender, length of stay (LOS), duration of the surgery, and anesthesia. Episode counts and individual antiemetic use are reported descriptively only; no inferential statistical comparisons were performed for these subgroup outcomes
At 24 h post-PACU, the incidence of PONV was not statistically significant between the two groups {19 (59%) patients in the hybrid group vs. 14 (42%) patients in propofol-only TIVA group (p = 0.17)} (Table 2). Subcategories of nausea, retching, and vomiting are reported descriptively; a total of 30 vs.
50 episodes of nausea, 3 vs. 8 episodes of retching, and 6 vs. 19 episodes of vomiting were observed in the hybrid and TIVA groups, respectively.
Antiemetic medications used 24 h post-PACU included ondansetron, prochlorperazine, promethazine, and scopolamine patch. Antiemetics were used by 16 patients in the hybrid group and 13 patients in the propofol-only TIVA group. (Table 2)
After adjusting for patients’ age, gender, LOS, duration of the surgery, and anesthesia, adjusted odds ratios for PONV and antiemetic use in PACU and within 24 h postoperatively were not statistically significant (Table 2). These exploratory analyses did not demonstrate an association between anesthetic group and PONV or antiemetic use.
Discussion
In this randomized trial of high-risk patients with a history of PONV and/or motion sickness undergoing general anesthesia for elective laparoscopic surgery, we found no statistically significant difference in the incidence of PONV in PACU or within 24 h of PACU discharge between a hybrid anesthetic technique using low-dose propofol infusion with sevoflurane and propofol-based TIVA. Rescue antiemetic use was also similar between the two groups.
Our PONV rates in PACU (21.2% in TIVA and 28.1% in hybrid) and at 24 h (42.4% in TIVA vs. 59.4% in hybrid) were lower than many published rates for volatile anesthesia alone in laparoscopic surgery, consistent with the well-established antiemetic property of propofol [9]– [10]. These findings align with earlier studies that have demonstrated that partial replacement of volatile anesthetics with propofol may attenuate the risk of early PONV and that TIVA may not offer a substantial incremental benefit over hybrid anesthetic technique in terms of preventing PONV [7, 11, 12].
Bansal et al. reported no significant difference in PONV between hybrid anesthesia and TIVA in female patients undergoing laparoscopic surgery [12]. Uchinami et al. similarly found comparable rates of PONV when a volatile anesthesia was combined with propofol infusion versus TIVA [7]. Our study is different from these earlier investigations as it focused on a higher-risk cohort and applied guideline-recommended antiemetic prophylaxis to all patients.
The non-significant difference in 24-hour PONV incidence (42.4% in TIVA vs. 59.4% in hybrid) in this high-risk cohort, despite prophylaxis with dexamethasone and ondansetron, suggests that a ceiling effect may exist with propofol-based anesthetic technique. Although adjusted exploratory analyses did not demonstrate a statistically significant association between anesthetic group and 24-hour PONV, the numerically higher incidence observed in the hybrid arm may reflect chance variation in a small sample.
In studies of this size, a small number of patients experiencing multiple PONV episodes can disproportionately influence cumulative event counts. Additionally, variability in postoperative management, including exposure to rescue antiemetics, and differences in surgical and anesthetic duration and LOS may have contributed to residual confounding despite adjustment. Accordingly, these findings should be interpreted as hypothesis-generating rather than conclusive.
This study focuses on a high-risk population that is under-represented in anesthesia trials. We standardized anesthesia protocols and administered consistent antiemetic prophylaxis to all patients in an effort to reduce confounding from variable intraoperative practices; however, there are several limitations that merit consideration. First, the sample size was small and was not powered to detect small-to-moderate differences in the incidence of PONV.
As such, the absence of statistically significant differences-particularly for 24-hour PONV- may reflect Type II error rather than true equivalence between anesthetic techniques. Second, this was a single center study, which may limit generalizability. Third, knowledge of group allocation by administering anesthesiologist could have introduced treatment bias, which cannot be fully mitigated by objective outcome collection.
Fourth, the absence of a volatile-only control group precludes definitive conclusions regarding whether adding low-dose propofol to sevoflurane is equivalent to replacing volatile anesthesia with TIVA. Fifth, patients in the propofol-only TIVA group experienced significantly longer surgical and anesthetic durations as well as longer hospital LOS, all of which are known risk factors for PONV. Although adjusted analyses were performed, these imbalances may have confounded comparisons despite randomization.
Sixth, postoperative rescue antiemetic administration was not protocolized and was left to clinician discretion, introducing heterogeneity that limits interpretability of secondary outcomes and increases susceptibility to Type II error. Finally, assessment of PONV during the 24 h follow up period relied on patient self-reporting. While patients were provided with a standardized data sheet and contacted by a blinded team member, responses were vulnerable to recall bias and symptom misclassification, particularly for transient and mild symptoms, potentially leading to under or over reporting of symptoms.
Future multicenter trials with larger sample sizes are needed to confirm these findings. Additionally, comparing the use of low-dose propofol + sevoflurane to sevoflurane alone in high-risk patients may further clarify whether the addition of propofol can mitigate the known emetogenic effects of volatile anesthetics. It would also be valuable to examine the incidence of PONV beyond 24 h after surgery, as this period was not included in our study.
Further investigation on the differential dosing of propofol with sevoflurane is needed to help elucidate whether a threshold or dose-dependent relationship exists by which propofol attenuates sevoflurane’s known emetogenic effects, or whether a certain dose can prolong the antiemetic effects of propofol.
Conclusion
Low-dose propofol combined with sevoflurane resulted in PONV rates that were not statistically different from propofol-based TIVA in high-risk patients receiving standardized prophylaxis.